word count: 242 22 Text word count: 3,127 23 SARS-CoV-2 3CL pro reporter assay 2 ABSTRACT 24In late 2019 a human coronavirus, now known as SARS-CoV-2, emerged, likely from a zoonotic 25 reservoir. This virus causes COVID-19 disease, has infected millions of people, and has led to 26 hundreds of thousands of deaths across the globe. While the best interventions to control and 27 ultimately stop the pandemic are prophylactic vaccines, antiviral therapeutics are important to limit 28 morbidity and mortality in those already infected. At this time, only one FDA approved anti-29 SARS-CoV-2 antiviral drug, remdesivir, is available and unfortunately, its efficacy appears to be 30 limited. Thus, the identification of new and efficacious antivirals is of highest importance. In order 31 to facilitate rapid drug discovery, flexible, sensitive, and high-throughput screening methods are 32 required. With respect to drug targets, most attention is focused on either the viral RNA-dependent 33 RNA polymerase or the main viral protease, 3CL pro . 3CL pro is an attractive target for antiviral 34 therapeutics as it is essential for processing newly translated viral proteins, and the viral lifecycle 35 cannot be completed without protease activity. In this work, we present a new assay to identify 36 inhibitors of the SARS-CoV-2 main protease, 3CL pro . Our reporter is based on a GFP-derived 37 protein that only fluoresces after cleavage by 3CL pro . This experimentally optimized reporter assay 38 allows for antiviral drug screening in human cell culture at biosafety level-2 (BSL2) with high-39 throughput compatible protocols. Using this screening approach in combination with existing drug 40 libraries may lead to the rapid identification of novel antivirals to suppress SARS-CoV-2 41 replication and spread. 42 43 44 SARS-CoV-2 3CL pro reporter assay